
San Diego-based Tandem launched the pairing of its flagship automated insulin delivery system with Control-IQ+ technology with Abbott’s latest continuous glucose monitor (CGM) sensor in the U.S. in October 2025.
This launch expands the combination of the automated insulin delivery system and CGM in the UK, Switzerland, Sweden, Finland and Italy. Additionally, Tandem aims to bring the integration to Belgium, the Netherlands and Germany later this year.
Get the full story at our sister site, Drug Delivery Business News.
